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Abstract
OBJECTIVES: Forty percent of women with ovarian carcinoma have circulating free neoplastic DNA identified in
plasma. Angiogenesis is critical in neoplastic growth and metastasis. We sought to determine whether circulating
neoplastic DNA results from alterations in the balance of angiogenesis activators and inhibitors. METHODS: Sixty
patients with invasive ovarian carcinomas with somatic TP53 mutations that had been characterized for circulating
neoplastic DNA had carcinoma analyzed for microvessel density using immunohistochemistry with CD31 and for
the expression of VEGF, ANGPT1, ANGPT2, PTGS2, PLAU, THBS1, CSF1, PIK3CA, HIF1A, IL8, MMP2, and MMP9
message by real-time quantitative polymerase chain reaction. The expression of each gene was calculated relative
to GAPDH expression for each neoplasm. Patient plasma had been tested for circulating neoplastic DNA using a
ligase detection reaction. RESULTS: MMP2 expression was significantly correlated with free plasma neoplastic
DNA (P = .007). Microvessel density was not correlated with plasma neoplastic DNA or BRCA1/2 mutation status.
The expression pattern of other angiogenic factors did not correlate with plasma neoplastic DNA but correlated
with each other. BRCA1/2 mutated carcinomas had significantly different expression profiles of angiogenesis
activators and inhibitors in comparison to sporadic carcinomas. CONCLUSIONS: MMP2 expression is associated
with the presence of circulating neoplastic DNA in women with ovarian carcinoma. These data are consistent with
the proinvasive properties ofMMP2 and suggest that the presence of circulating neoplastic DNA indicates a more
aggressive malignant phenotype. Carcinomas with germ line BRCA1/2 mutations had a lower angiogenic profile
than those without mutations.
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Introduction
Ovarian carcinoma is the most common cause of death among
women with a gynecologic cancer in the United States [1]. Most
women present with an advanced stage of disease and have lymph
node or intraperitoneal metastasis at the time of diagnosis. The 5-year
survival for advanced-stage disease (i.e., stage III-IV) ranges from 18%
to 40% [2].
Circulating cell-free neoplastic DNA has been identified in the
plasma of 17% to 44% of patients with ovarian carcinoma [3–5].
The origin of neoplastic DNA in the circulation is unknown. Several
hypotheses have been advanced to explain this phenomenon, includ-
ing lysis of circulating neoplastic cells or micrometastases, tumor
necrosis, apoptosis, or spontaneous active release of DNA by the ma-
lignancy into the bloodstream [6]. The presence of free neoplastic
DNA in the plasma of women with ovarian carcinoma has been linked
to poor outcome and diminished survival [3,4,7,8].
The pattern of metastases in ovarian, peritoneal, and fallopian tube
carcinoma is different from that of other solid malignancies. Ovarian
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carcinomas spread predominantly by direct dissemination in the
peritoneal cavity or through local lymphatic channels and rarely by
hematogenous spread [9]. The role of various proinvasive proteolytic
enzymes and angiogenesis activators and inhibitors has been studied
in ovarian carcinomas, including matrix metalloproteinases (MMPs),
a large family of zinc-dependant endopeptidases capable of degrading
extracellular matrix and basement membrane components [10].
MMPs have been implicated in neoplastic growth, invasion, and
metastasis [11,12]. Expression of MMP2, a protease responsible for
the control of various collagens (including the degradation of type IV
collagen) that make up the extracellular matrix, is elevated in ovarian
carcinoma compared to borderline or benign ovarian neoplasms, sug-
gesting a role in carcinogenesis [13,14]. Overexpression of MMP2
in neoplastic cells of peritoneal implants in ovarian cancer patients
has been associated with an increased risk of death [13].
Angiogenesis is also critical in neoplastic growth and metastasis.
VEGF is a cytokine that functions to increase microvascular per-
meability and stimulate endothelial cell growth and angiogenesis
[15,16]. Increased production of VEGF has been implicated in
tumorigenesis, metastasis, and the production of malignant effu-
sions by increasing vascular permeability [16,17]. Rudlowski et al.
[18] associated enhanced VEGF expression in ovarian carcinoma
ascites with reduced progression-free and overall survival. Increased
microvessel density (MVD), another marker of angiogenesis, is
also associated with worse prognosis in most studies in ovarian
carcinomas [19].
We sought to determine whether the presence of circulating neo-
plastic DNA is associated with alterations in the balance of angio-
genesis activators and inhibitors in ovarian carcinoma. In addition,
we correlated the expression of angiogenesis genes in the carcinoma
with the presence of germ line BRCA1 and BRCA2 (BRCA1/2)
mutations to assess for possible differences among this cohort. There
have been many studies that report improved survival in patients
with BRCA1/2–associated ovarian carcinoma in comparison to pa-
tients with sporadic ovarian carcinoma [20–24]. We wanted to assess
the angiogenic profile in BRCA1/2–mutated carcinomas that might
explain a potential survival advantage and afford insight into possible
treatment strategies.
Materials and Methods
Patients and Specimens
Blood, neoplastic tissue, clinical information, and follow-up data
were collected by the University of Washington Gynecologic On-
cology Tissue Bank as approved by the Human Subjects Committee
of the Institutional Review Board. Ovarian carcinomas that had been
previously sequenced for somatic TP53 mutations and characterized
for circulating neoplastic DNA were identified. Platinum resistance
was defined as less-than-a-complete response to chemotherapy or
relapse within 6 months of completing chemotherapy. Carcinomas
were surgically staged according to the International Federation of
Obstetrics and Gynecology (FIGO) criteria [25]. Optimal surgical
debulking was defined as no residual neoplasm greater than 1 cm
in diameter. Overall survival was defined as the interval between
diagnosis and death or diagnosis and last observation. Data were cen-
sored at the last follow-up. BRCA1/2 mutations were characterized
using targeted selection and massively parallel genomic sequencing as
previously reported [26].
DNA Sequencing and Ligase Detection Reaction
DNA had previously been extracted using the QIAamp DNA
Mini kit (Qiagen, Valencia, CA) as previously described, and plasma
DNA was quantified after extraction with the PicoGreen dsDNA
Quantification Kit (Molecular Probes, Inc, Eugene, OR) [3,27].
Sequencing using polymerase chain reaction (PCR) amplified for all
TP53 coding exons (4-10) and flanking regulatory regions had also
been performed. Finally, the sensitive ligase detection reaction pre-
viously reported was used to evaluate the target TP53 sequence [3].
Immunohistochemistry
Sixty ovarian carcinomas were analyzed for MVD using immuno-
histochemistry with CD31 as previously described [19]. MVD at
400× magnification was stratified into high (>15 vessels/high-power
field) versus low (≤15 vessels/high-power field) counts.
Angiogenic Marker Expression
Quantitative messenger RNA expression of VEGF, ANGPT1,
ANGPT2, PTSG2, PLAU, THBS1, CSF1, HIF1A, IL8, MMP2, and
MMP9 was assessed using real-time quantitative reverse transcription–
PCR. Reverse transcription–PCR was performed using complementary
DNA, TaqMan probes (Applied Biosystems, Carlsbad, CA), and the
TaqMan Universal PCR Kit (Applied Biosystems) and run on the ABI
Prism 7900 sequence detection system (Applied Biosystems). Expression
was calculated relative to GAPDH expression for each neoplasm.
Statistical Analysis
Statistical analyses were performed with StatView (SAS, Cary, NC) and
Prism 4 (GraphPad Software, San Diego, CA). Contingency tables were
evaluated with Fisher exact test or Pearson χ2 test. Two-sided Student’s
t test with P < .05 was used to determine statistical significance, and the
Cox proportional hazards model was used for multivariate analysis. Over-
all survival was calculated according to the methods of Kaplan and Meier.
Results
Study Population
Sixty patients with ovarian carcinoma were identified with known so-
matic TP53mutations. Characteristics of the study subjects are detailed in
Table 1. Twenty-three patients (38.3%) had free neoplastic DNA iden-
tified in plasma using the ligase chain reaction for their specific somatic
TP53 mutation as previously reported [3]. Nine patients (14.8%) had
identified germ line BRCA1/2mutations (four BRCA1 and five BRCA2).
Most patients had advanced-stage disease, 80% presenting with
stage III. Most subjects (97%) had grade 3 carcinomas and serous histo-
logic diagnosis (70%). Slightly more than half (53%) were optimally de-
bulked. All but three patients received adjuvant chemotherapy. Of those
receiving chemotherapy, 54 patients (90%) received a platinum-taxane
combination. One patient had an unknown chemotherapeutic regimen.
Of the three who did not receive adjuvant therapy, one had stage IA
and two refused (one with stage IIIB and one with stage IIIC disease).
All patients had a preoperative CA-125 level greater than 35 U/ml.
Association of Neoplastic DNA in Plasma and
Known Prognostic Factors
The presence of neoplastic plasmaDNAwas not associated with known
prognostic factors including BRCA1/2 mutation status, lymph node
metastasis (odds ratio = 0.70, 95% confidence interval [CI] = 0.24-
2.04, P = .59), stage IV disease (OR = 2.48, 95% CI = 0.63-9.73,
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P = .30), suboptimal cytoreduction (OR = 0.64, 95% CI = 0.29-1.44,
P = .32), or platinum resistance (37% vs 43%, P = .78). However, there
was a borderline association of detectable circulating neoplastic DNA and
the likelihood of complete response to initial chemotherapy (86%
vs 61%, P = .07). Two patients (8.7%) with circulating neoplastic
DNA developed brain metastases versus one patient (2.7%) in the
group without free neoplastic DNA. Whereas the association of cir-
culating neoplastic DNA and brain metastases was not statistically sig-
nificant (P = .57, OR = 2.97, 95% CI = 0.26-34.26), the incidence in
both groups exceeded that predicted for ovarian cancer (<1%).
Association of Angiogenesis Activators and Inhibitors with
Circulating Neoplastic DNA
MMP2 expression was significantly correlated with circulating neo-
plastic DNA in plasma (P = .007; Figure 1). The expression of other
angiogenic factors did not correlate with plasma neoplastic DNA but
did significantly correlate with one another. Expression of MMP2 was
thus significantly associated with expression ofMMP9 and other angio-
genesis activators. Expression of the various angiogenesis activators and
inhibitors was not associated with MVD, andMVD was not associated
with the presence of neoplastic DNA in plasma or BRCA1/2 mutation
status. Increased MVD did not correlate with overall survival.
Carcinomas with Germ Line BRCA1/2 Mutations
Have a Different Expression Profile of Angiogenesis
Activators and Inhibitors
Ovarian carcinomas with known germ line BRCA1/2 mutations
had expression profiles of angiogenesis activators that differed signif-
icantly from those of neoplasms without these mutations. Relative
Figure 1. Relative MMP2 expression in ovarian carcinomas was
significantly higher in womenwith circulating neoplastic DNA com-
pared to those without detectable circulating neoplastic DNA.
Figure 2. Expression of proangiogenesis modulators in sporadic
ovarian carcinomas compared to those with germ line BRCA1/2
mutations. (A) Relative VEGF expression was significantly lower
in cases with BRCA1/2 mutations. (B) Relative PLAU expression
was significantly lower in cases with BRCA1/2 mutations. (C) Rel-
ative CSF1 expression was significantly lower in cases with
BRCA1/2 mutations.
Table 1. Case Characteristics.
Characteristics Total (N = 60) Plasma DNA+ (n = 23) Plasma DNA− (n = 37)
Age, years
Median 57 55 64
Range 28-88 28-88 37-88
Survival, months
Mean 39 35 39
Range 1-118 1-89 4-118
FIGO stage, n (%)
I 2 (3.3) 0 2 (5.4)
II 1 (1.7) 1 (4.3) 0
III 48 (80) 17 (73.9) 31 (83.8)
IV 9 (15) 5 (21.7) 4 (10.8)
Histologic diagnosis, n (%)
Serous 42 (70) 14 (60.9) 28 (75.7)
Adenocarcinoma NOS 11 (18.3) 5 (21.7) 6 (16.2)
Clear cell 1 (1.7) 0 1 (2.7)
Endometrioid 2 (3.3) 1 (4.3) 1 (2.7)
Carcinosarcoma 2 (3.3) 2 (8.7) 0
Other 2 (3.3) 1 (4.3) 1 (2.7)
Grade, n (%)
1 1 (1.7) 0 1 (2.7)
2 1 (1.7) 1 (4.3) 0
3 58 (96.7) 22 (95.6) 36 (97.3)
Optimal, n (%)
Yes 32 (53.3) 15 (65.2) 18 (48.6)
No 28 (46.7) 8 (34.8) 19 (51.4)
TP53 mutation, n (%)
Missense 44 (73.3) 17 (73.9) 27 (73)
Null 15 (25) 5 (21.7) 10 (27)
Splice 1 (1.7) 1 (4.3) 0
BRCA1/2 mutation, n (%)
Total 9 (14.8) 6 (26.1) 3 (8.1)
BRCA1 4 (6.7) 3 (13.0) 1 (2.7)
BRCA2 5 (8.3) 3 (13.0) 2 (5.4)
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expression of the following proangiogenesis modulators was de-
creased in carcinomas with BRCA1/2 mutations: VEGF (P = .008),
PLAU (P = .01), and CSF1 (P = .008) (Figure 2). The relative
expression of the proangiogenesis factors MMP2 (P = .09), MMP9
(P = .21), PTGS2 (P = .06), and IL8 (P = .09) was also decreased in
BRCA1/2–positive neoplasms, but the findings did not reach statis-
tical significance. In further analysis of angiogenesis activators and
inhibitors in BRCA1/2–mutated carcinomas, the relative expression
of VEGF was significantly decreased in BRCA2 carcinomas in com-
parison to those with BRCA1 mutations (P = .03). One case had a
somatic BRCA1 mutation (3593 delT) and had a higher angiogenic
profile consistent with the wild-type sporadic carcinomas.
Discussion
In our series, increased MMP2 expression was associated with circu-
lating neoplastic DNA in plasma, consistent with our hypothesis that
specific angiogenesis factors would influence the presence of circulat-
ing, cell-free neoplastic DNA and result in a more aggressive malig-
nant phenotype. Modulators of MMP2 expression such as MMP14,
TIMP2, and MMP7 are upregulated in ovarian carcinomas, as is
MMP2 expression itself [14,28]. MMP2 cleavage of extracellular
matrix proteins is believed to enhance adhesion of malignant cells to
the peritoneum and thereby promote metastasis and invasion [29].
MMP2 overexpression has been correlated with elevated histologic
grade and advanced stage in ovarian carcinoma and is thus considered
a potential marker for proliferation, invasiveness, and metastasis [30].
Although several studies have suggested that overexpression of MMP2
in ovarian carcinoma is associated with poor survival, we did not detect
a significant difference in survival among patients with a high expres-
sion of MMP2, but this was too small a cohort to detect moderate
survival effects [13,31,32].
We and others have previously demonstrated that circulating
tumor-derived DNA in the plasma of women with ovarian carcinoma
portends for worse overall survival [3,4,7]. The current literature also
suggests that cell-free neoplastic DNA may be associated with de-
creased progression-free survival and poor response to chemotherapy,
in particular if elevated levels are detected after the initial treatment
[8]. In accordance with that observed in the literature, 38.3% of our
cohort had circulating neoplastic DNA identified in plasma. These
patients did not demonstrate increased incidence of lymph node
metastasis, stage IV disease, or suboptimal cytoreduction. In our
cohort, there were three patients who developed brain metastasis,
and although the results did not reach statistical significance, the inci-
dence of brain metastasis (8.7%) was tripled in women with detectable
cell-free neoplastic DNA in plasma, suggesting that cases with free
neoplastic DNA in plasma may exhibit more hematogenous spread.
We suggest that increasedMMP2 expression may be the common link
underlying worse prognosis and more aggressive spread patterns in
cases with circulating neoplastic DNA.
Although MMP2 expression correlated with circulating neoplastic
DNA, the expression of other angiogenesis activators did not. The
expression of all the angiogenic factors did correlate highly with each
other, and in carcinomas with high levels of MMP2 activity, levels of
the various other angiogenic factors were also elevated. These data
suggest that an aggressive malignant phenotype is mediated through
a complex interplay of proteolytic enzymes and angiogenesis-promoting
growth factors but that MMP2 may be the driving force that allows
neoplastic DNA into the circulation.
Interestingly, ovarian carcinomas with germ line BRCA1 or BRCA2
mutations have a lower expression profile of angiogenesis activators.
Levels of VEGF, PLAU, and CSF1 were all significantly lower in car-
cinomas from women with germ line BRCA1/2 mutations, and there
was a trend toward lower values of all other studied angiogenesis acti-
vators, including MMP2. These data are the first report of decreased
expression of angiogenesis-promoting growth factors and proinvasive
proteolytic enzymes in ovarian carcinomas associated with germ line
BRCA1/2mutations. Interestingly, the one case with a somatic BRCA1
mutation had a higher angiogenic profile, suggesting that germ line
and somatic BRCA1/2 mutations may not be equivalent in relation
to an angiogenic phenotype. In comparing BRCA1 and BRCA2 carci-
nomas, VEGF expression was significantly lower in BRCA2-mutated
cases. A recent analysis by Bolton et al. [20], demonstrates improved
survival in patients with BRCA1/2 carcinomas compared to sporadic
controls with the best prognosis for women with BRCA2 mutations.
Other smaller studies have reported similar findings [21–24]. Most
authors have attributed increased survival in women with BRCA1/2–
mutated ovarian carcinoma to improved response to platinum-based
therapy; a less angiogenic phenotype could represent an alternative or
supplementary explanation. The decreased level of VEGF expression
in ovarian carcinomas with germ line BRCA2mutations could contrib-
ute to a less aggressive phenotype in this subgroup. The number of
BRCA1/2–mutated carcinomas in our cohort was small (nine patients),
and these findings should be confirmed in a larger cohort as they could
have therapeutic implications with regard to the use of angiogenesis
inhibitors in different patient subsets.
In conclusion, our data suggest that cell-free neoplastic DNA gains
access to plasma at least in part due to MMP2 overexpression. MMP2
overexpression, in addition to circulating neoplastic DNA, may thus be
a marker for a more aggressive neoplastic phenotype. Levels of various
angiogenesis activators were diminished in carcinomas with germ line
BRCA1/2mutations and may thus indicate a less aggressive phenotype,
although this warrants verification in a larger patient cohort.
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